Promakhos Therapeutics (YC S21) — A therapeutics platform for curing inflammatory disorders
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B.
Promakhos Therapeutics is a Y Combinator company in the Summer 2021 batch. Its directory entry describes it as: A therapeutics platform for curing inflammatory disorders. The founders listed are Katerina Chatzi (Founder), Jasper Edgar Neggers (Founder) (Y Combinator directory entry, July 22, 2021).
Get an email when Promakhos Therapeutics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Promakhos Therapeutics?
Get the full cited report on Promakhos Therapeutics
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
Katerina Chatzi
Founder
Jasper Edgar Neggers
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Promakhos Therapeutics?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Promakhos Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Promakhos Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Promakhos Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
